Update on clinical trials in the treatment of hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue SUPPL., 1999, Pages

  Pessoa, Mario G ^a   Wright, Teresa L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Interferon; Nucleoside analogues; Viral hepatitis

Indexed keywords

ACICLOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; FAMCICLOVIR; FLUOROTHIACYTADINE; GAMMA INTERFERON; GANCICLOVIR; HEPATITIS B VACCINE; INTERLEUKIN 2; LAMIVUDINE; LEVAMISOLE; LOBUCAVIR; NUCLEOSIDE; NUCLEOSIDE ANALOG; PENCICLOVIR; PREDNISONE; THYMOSIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; ASIA; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS B; HUMAN; INFLUENZA; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0033012325     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01877.x     Document Type: Article

References (30)

1. Beasley R, Ling C, Hwang L et al. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22 707 men in Taiwan. Lancet 1981; ii: 1129-33.
2. Wright T, Lau J. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342: 1340-5.
3. Niederau C, Heinges T, Lange S et al. Long-term follow-up of the HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. M. Engl. J. Med. 1996; 334: 1422-7.
4. Lau J, Wright T. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335-40.
5. Perrillo R, Schiff E, Davis G et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 1990; 323: 295-301.
6. Wong D, Cheung A, O'Rourke K, Naylor C, Detsky A, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 1993; 119: 312-23.
7. Lok A, Lai C, Lau J. Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver. Gastroenterology 1991; 100: 756-61.
8. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S. Long term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interfcron alpha. Hepatology 1997; 26: 1338-42.
9. Perrillo RP, Tamburron C, Regenstein F et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908-16.
10. Villeneuve J, Desrochers M, Infante-Rivard L et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106: 577-80.
11. Lampertico P, Ninno E, Manzin A et al. A randomized, controlled trial of a 24 month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 1621-5.
12. Davis G. Interferon treatment of viral hepatitis in immunocompromised patients. Semin. Liver Dis. 1989; 9: 267-72.
13. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive hepatitis B. Ann. Intern. Med. 1995; 122: 664-75.
14. Dusheiko G, Roberts J. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology 1995; 22: 1863-73.
15. Ling R, Multimer D, Ahmed M et al. Selection of mutations in hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-13.
16. Lai CI, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61-8.
17. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
18. Dienstag J, Schiff E, Gitlin N et al. Extended lamivudine retreatment for chronic hepatitis B (abstract). Hepatology 1996; 24 (Suppl. 1): 188A.
19. Bartholomew M, Jansen R, Jeffers I, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2.
20. Main J, Brown J, Howells C et al. A double-blind, placebo controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hepat. 1996; 3: 211-15.
21. Trepo C, Jezek P, Atkinson G, Boon R. Efficacy of famciclovir in chronic hepatitis B. Results of a dose finding study (abstract). Hepatology 1996; 24: 188A.
22. Kruger M, Tillmann H, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplant. Surg. 1996; 2: 253-62.
23. Bloomer J, Chan R, Sherman M et al. Phase I/II study of oral lobucavir in adults with chronic hepatitis B infection. Second International Conference on Therapies for Viral Hepatitis, Hawaii, USA, December 1997; 2.
24. DeHertogh D, Colonno R, Grasela D. Lobucavir and BMS-200475: Two potent new agents for hepatitis B. Second International Conference of Therapies for Viral Hepatitis, Hawaii, USA, December 1997.
25. Gilson R, Chopra K, Murray-Lyon I er al. A placebo-controlled phase I/II study of adefovir dipivoxil (BIS-POM PMEA) in patients with chronic hepatitis B infection (abstract). Hepatology 1996; 24: 620A.
26. Virani-Ketter N. Adefovir dipivoxil for the treatment of chronic hepatitis B. Second International Conference on Therapies for Viral Hepatitis, Hawaii, USA, December 1997; 22.
27. Vitiello A, Ishioka G, Grey H et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J. Clin. Invest. 1995; 95: 341-9.
28. Heathcote J, McHutchison J, Benner K et al. CY-1899: A therapeutic vaccine for chronic hepatitis B (abstract). Hepatology 1996; 24: 628A.
29. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216-25.
30. Locarnini S, Aye T, Shaw T et al. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy in patients following liver transplantation (abstract). Hepatology 1997; 26: 368A.